Our news

Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical

Stockholm, Sweden, September 2, 2025 – AnaCardio, a Swedish clinical-stage

Alignment reached with both the FDA and EMA on key

Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 – AnaCardio,

February 25, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical

Reports positive results from phase 1b study of AC01 in

Stockholm, Sweden, September 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical

Stockholm, Sweden, June 3, 2024  AnaCardio, a Swedish clinical-stage biopharmaceutical

Stockholm, Sweden, April 4 , 2024 AnaCardio, a Swedish clinical-stage

Stockholm, Sweden, April 3, 2024 AnaCardio AB announces today the

AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel

Stockholm, Sweden, August 17, 2023  AnaCardio, a Swedish clinical-stage biopharmaceutical

Solna, Sweden and Lugano, Switzerland, April 13, 2023 AnaCardio, a

Stockholm, Sweden, March 14 , 2023  AnaCardio´s founder Prof Lars

Stockholm, Sweden, November 17, 2022 AnaCardio today announces approval for

Stockholm, Sweden, September 7, 2022 AnaCardio raises SEK 150 million

Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 Helsinn Group

Stockholm, Sweden, 3 February 2022 AnaCardio raises SEK 33 million

Stockholm Sweden – October 25, 2021 Karolinska Development’s portfolio company

Stockholm, Sweden, 22 October 2021 AnaCardio appoints Patrik Strömberg as

Stockholm, Sweden – June 17, 2021 Karolinska Development AB (Nasdaq